Who can Travoprost
Travoprost To reduce elevated intraocular pressure in patients with ocular hypertension or glaucoma otkrytouglovoy.
How do I use Travoprost
For ophthalmic use.
Dose
Application for the treatment of adults, including elderly patients.
1 drop of Travatan in the conjunctival sac of affected eye (eye) once a day. The optimum effect is achieved by administration of a dose in the evening.
After instillation is recommended nasolacrimal occlusion or tight shut eyelids. This reduces the systemic absorption of drugs introduced into the eye, which reduces the likelihood of systemic side effects.
If more than one local ophthalmic means the interval between their use should be at least 5 minutes.
If you are replacing another ophthalmic hypotensive funds for Travatan, the use of a drug is stopped and the next day start using Travatan.
Application for violations of liver and kidney function.
TRAVATAN was studied in patients with impaired liver function (from mild to severe), as well as in patients with renal impairment (from mild to severe) – creatinine clearance below 14 ml / min. No need to adjust the dose in such patients.
The patient should break the top protective packaging just prior to first use. To prevent contamination of the dropper tip and solution, you must be careful not to touch the eyelids, surrounding areas or other surfaces of the tip of the dropper bottle.
Features of Travatan.
Travatan may gradually change eye color by increasing the number of melanosomes (pigment granules) in melanocytes. Before starting treatment, patients should be informed about the possibility of irreversible changes in eye color. Treatment of one eye can lead to passing heterochromia. The consequences of long-term effects on melanocytes are not currently known. Change the color of the iris is slow and may not be visible for months or years. Change the color of your eyes, above all, have been noted in patients with a mixed color of the iris, for example, blue-hazel-gray hazel, yellow-hazel, and green-hazel, but this phenomenon was also observed in patients with brown eyes. Typically, the brown pigmentation around the pupil concentrically to disperse to the periphery of the iris of the affected eye, but the entire iris or part of it could get more intense brown color. After cessation of treatment to further increase brown pigment in the iris were observed.
In controlled clinical trials in 0.4% of the patients was observed darkening of the eyelid skin and / or periorbital area in connection with the use of travoprost.
Travatan may gradually change the structure of the eye lashes to which is applied, and such changes were observed in half of patients in clinical studies and include increased length, thickness and pigmentation, and / or number of lashes. Mechanism for changing the structure of lashes, and long-term consequences of this effect is currently unknown.
Travatan, as was demonstrated in studies has caused a slight extension of the palpebral fissure in monkeys. However, this effect was not observed in clinical trials and is regarded as species specific.
No experience with travoprost in inflammatory diseases of the eye, and neovascular glaucoma, narrow-angle glaucoma, or closure of congenital glaucoma, there is only limited experience with exophthalmos associated with thyroid disease, with open-angle glaucoma in patients with psevdofakiey, with pigmentary glaucoma or pseudoexfoliative.
Recommended to be prescribed with care travoprost patients with aphakia, psevdofakiey and break the back of the lens capsule and anterior chamber lens or in patients with known risk factors for macular edema.
Avoid contact with skin Travatan, as in experiments on rabbits demonstrated the transdermal absorption travoprost.
Benzalkonium chloride, which is commonly used as a preservative in ophthalmic preparations, according to reports, may provoke point keratopathy and / or toxic keratopathy ulcer. Because Travatan contains benzalkonium chloride, needs careful monitoring with frequent or prolonged treatment, the drug in patients with dry eyes in situations where a damaged cornea.
Should be carefully administered to patients with travoprost known risk factors for Irita / uveitis.
Because Travatan contains a preservative benzalkonium chloride, the latter may provoke irritation and is known to discolour soft contact lenses. Therefore, patients should remove contact lenses before burying Travatan, and be informed about what is necessary to wait 15 minutes after instillation travoprost and only insert contact lenses.
Pregnancy
No adequate data on the use travoprost pregnant women. Animal studies have demonstrated toxic effects on reproductive function. The potential risk for humans has not been studied. So, Travatan is not recommended during pregnancy without any apparent need.
Women of childbearing age Travatan should not be applied to women of childbearing age, if they do not use contraceptives.
Lactation
Animal studies have shown that travoprost and its metabolites can cross into breast milk, so use Travatan during lactation is not recommended.
Used to treat children and adolescents
Efficacy and safety Travatan patients under 18 years has not been proven, so should not be used by these patients to receive new data.
Impact on driving ability or other mechanical means. As with other eye drops, temporary blurred vision or other visual disturbances may affect your ability to drive or operate machinery. If blurred vision occurs at instillation, the patient must wait until the vision becomes clear only later to drive or operate machinery.
Side effects Travoprost
In clinical trials on more than 1100 patients Travatan was administered twice daily as monotherapy or as an adjuvant in conjunction with timolol 0.5%. None of the clinical trials there were no reports of any serious ocular or systemic adverse effects associated with the use of Travatan. Most often, there were reports of such undesirable effects associated with use of the drug as eye redness (36.6%), which was mild in 92.4% of patients who reported about this effect. Number of cases of drug discontinuation due to flushing eyes makes 2,3%. In the third phase of clinical trials of 6 to 12 months hyperemia decreased with time.
In clinical studies travoprost were reported the following adverse events, which were estimated as the unquestionably likely or possibly associated with the use of the drug. Their appearance was, or very frequent (10%), frequent (ranging from 1% to 10%, the maximum number of cases, 4.7%) or single (from 0,2% to less than 1%). Message to all other effects were isolated, none of them it was not about serious side effects and side effects associated with the use of the drug.
Ophthalmic effects
Very common: flushing eyes.
Common: itching, discomfort (burning or tingling sensation passing after instillation), eye pain, dry eyes, photophobia, foreign body sensation in the eye, opalescence, discoloration of the iris and keratitis precipitates.
Singles: watery eyes, blurred vision, changes in the structure of eyelashes, conjunctivitis, eye irritation, decreased visual acuity, iritis, swelling of the eyelids, a sense of sticking together, blepharitis, pain in the superciliary arches, conjunctival follicles, conjunctival papillae, peeling on the edges of the eyelids, eye fatigue and uveitis .
- Systemic effects
- Organism as a whole
- Common: headache.
- Circulatory system
- Singles: hypotension, bradycardia.
- Skin and appendages
- Liquid: discoloration of the skin periorbital area.
As with other prostaglandin analogues (the action of this class), Travatan may gradually change the structure of the eye lashes, which will be installed, similar changes were observed in more than half of patients in clinical trials and included: increased length, thickness, pigmentation and / or the number of lashes. Mechanism for changing the structure of lashes, and long-term consequences of this effect is currently unknown.
Who is contraindicated Travoprost?
Hypersensitivity to travoprost or other ingredients.
Interaction Travoprost
Travatan interaction with other drugs is not yet rated. Study of specific interactions in vitro were carried out with Travatan and preparations containing thiomersal. Evidence of precipitation was not observed.
Data regarding the use travoprost in combination with 0.5% timolol, and the limited data on its use in combination with brimonidinom 0,2%, obtained in clinical trials have demonstrated the additional step of Travatan when used with these hypotensive drugs. No clinical evidence of simultaneous application with other antihypertensive drugs.
Overdose Travoprost
If overdose is necessary to symptomatic treatment.
